Neurological disorders – including Parkinson’s – are leading source of disability globally
Author: Almaz OhenePublished: 16 November 2017
Prep: Cook: Serves:
New research published this week in the journal ‘JAMA Neurology’ by Professor Bastiaan Bloem, from Radboud University Nijmegen Medical Centre in the Netherlands, and Dr Ray Dorsey from University of Rochester Medical Center, shows that neurological disorders are now the leading source of disability worldwide
The medical community must mobilise to respond to the predicted rapid increase in people living with Parkinson’s over the next twenty years, argue leading Parkinson’s specialists Professor Bastiaan Bloem and Dr Ray Dorsey in a journal article this week.
In an article called ‘Parkinson Pandemic – A Call to Action’ in the journal ‘JAMA Neurology’ earlier this week, the expert physicians point out that between 1990 and 2015, the prevalence of Parkinson’s more than doubled, with an estimated 6.9 million people worldwide living with the condition. They also estimate that by 2040, the number of people with Parkinson’s will increase to 14.2 million as the population ages.
In a bid to combat this growing pandemic, the authors argue that the medical community should pursue the same strategies that transformed HIV from an unknown and fatal illness, into a highly treatable chronic condition.
Dr Ray Dorsey, from the University of Rochester Medical Center, US, said: “Pandemics are usually equated with infectious diseases like Zika, influenza, and HIV – but neurological disorders are now the leading cause of disability in the world and the fastest growing is Parkinson’s disease.”
Their article echoes another study, the ‘Global Burden of Disease’, also co-authored by Dorsey, which appeared in ‘The Lancet Neurology’ in September. That study tracked the prevalence of neurological diseases such as Parkinson’s, Alzheimer’s, stroke, epilepsy, meningitis, encephalitis, multiple sclerosis, and migraine, both globally and by individual country.
Professor Bastiaan Bloem, of the Radboud University NijmegenMedical Centre, the Netherlands, said: “People with HIV infection simply demanded better treatments and successfully rallied for both awareness and new treatments, literally chaining themselves to the doors of pharmaceutical companies. Today, HIV has become a treatable, chronic disease. This upcoming increase in the number of Parkinson’s patients is striking, and frankly, worrisome. We feel it is urgent that people with Parkinson’s go to the pharmaceutical industry and policymakers alike, demanding immediate action to fight this enormous threat.”
Dr Dorsey continued: “For too long Parkinson’s community has been too quiet on these issues. Building on the AIDS community’s motto of ‘silence equals death’, Parkinson’s community should make their voices heard. The current and future burden of this debilitating disease depends upon their action.”
The two academics argue that access to care for Parkinson’s – a highly treatable condition – is also limited. In the US for example, more than 40% of individuals with Parkinson’s over the age of 65 do not see a neurologist, while an online survey of 35 European countries showed that 40% of respondents had never seen a Parkinson’s specialist. In less wealthy nations, many are never diagnosed. In a door-to-door study in Bolivia, none of the individuals found to have the condition had ever been diagnosed or received treatment.
Todd Sherer, CEO of The Michael J Fox Foundation, said: “Too many people have Parkinson’s today and more will face diagnoses tomorrow. We all – government, patient organisations, researchers, doctors and patients – must work together for better care for those living with this disease and research toward a future without Parkinson’s.”
Dr Ray Dorsey Dr Ray Dorsey is David M Levy professor of neurology and director of the Center for Health and Technology at the University of Rochester Medical Center, US, where he is helping investigate new treatments for movement disorders and improve the way care is delivered for people with Parkinson and other neurological disorders.
Dr Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins, Maryland, US. Dr Dorsey’s research has been published in the leading medical, neurology, and economic journals and has been featured in The New York Times, and The Wall Street Journal.
Image credit: University of Rochester Medical Center
Professor Bastiaan Bloem Baastian Bloem is a consultant neurologist at the Department of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands. In 1994, he obtained his PhD degree at the Leiden University Medical Centre, the Netherlands. In 2002, he founded and became medical director of Parkinson Centre Nijmegen (ParC), the Netherlands, which was recognised from 2005 onwards as centre of excellence for Parkinson’s disease.
Together with Dr Marten Munneke, he also developed ParkinsonNet, where people with Parkinson’s “co-design” their treatment programme in collaboration with a dedicated, multi-disciplinary team – accessed via ParkinsonNet’s online database of expert practitioners.
Share what you know about treatments for late-stage Parkinson’s disease
Take part in a survey from Parkinson's Europe and Britannia Pharmaceuticals
7 days ago
Investigational Parkinson’s disease dementia therapy fails in clinical trial
Research into new potential therapies for people with Parkinson’s is complex, which means that not all clinical trials will successfully move on to the next phase. This proved to be the case for US biotech company Aptinyx, which announced that it will halt further development work on an investigational therapy following “disappointing” results in the second phase of its study. The research had set out to examine the effect of NYX-458 – an oral therapy created to modulate the activity of receptors in the brain that are responsible for communication between neurons. The aim of the therapy was to improve cognition in people with cognitive impairment linked to Parkinson’s or Lewy body dementia. Yet, when compared to a placebo, the therapy didn’t demonstrate “meaningful improvements” in cognitive function. Dr Andy Kidd, president and CEO at Aptinyx, said: “We are very disappointed that the results of this Phase 2 study did…
A new intimacy guide aims to support people with Parkinson’s disease in the US
Does sexual wellness in the Parkinson’s community need more focus? It’s an area that the American Parkinson Disease Association (APDA) and media brand Havas Health Plus have targeted through the launch of a free intimacy guide. Available to people in the US, ‘The ParkinSex Booklet & Kit’ aims to support those whose relationships may have been impacted by emotional and physical distance linked to the condition. Alongside an educational guide, the kit includes items such as candles, coupons for adaptative clothing and massage stones. Following a positive response to an initial pilot distribution of the guides in the US, there is now a waitlist for future kits. Commenting on the launch in a press release, APDA president and CEO Leslie Chambers said: “The challenges of Parkinson’s can often result in intimacy and connection getting left behind. This is why we created ‘The ParkinSex Booklet & Kit’, to help people with…
How prevalent are non-visual hallucinations in Parkinson’s disease?
Some people in the later stages of Parkinson’s can experience hallucinations – “when you see, hear or feel things that aren’t there”. With most research into this topic centred on visual hallucinations, a team in Australia set out to investigate data around non-visual hallucinations in people with the condition. Published in the ‘Journal of Neurology’, the analysis drew on 91 relevant studies released between 1970 and 2022. The team found that visual hallucinations appeared to be most common, with an expected prevalence of up to 96.6%. Meanwhile, non-visual hallucinations – including auditory (relating to the sense of hearing) and olfactory (relating to the sense of smell) – had an estimated prevalence of up to 73.3%. Concluding that non-visual hallucinations may “impact a notable proportion” of people with the condition, the team said: “More direct research and clinical attention need to be devoted to the study and management of such hallucinatory…